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Background:  A vaccine for primary varicella (VZV) was licensed and recommended for use in 
children as a single dose in 1996, and as two doses in 2006.  A vaccine for herpes zoster (HZ) 
was licensed and recommended for use in adults >60 years in 2006.  Both vaccines have the 
potential to modify the epidemiology of VZV and HZ.  Rates of hospitalization due to VZV and 
HZ were examined in the post-vaccine era to characterize the epidemiology of severe disease and 
to assess the possible impact of vaccination on the incidence of hospitalization. 
Methods:  Statewide hospital discharge data in Connecticut were used to identify cases of VZV 
and HZ from 1994-2012. Trends in hospitalization rates were assessed using Poisson regression 
models or Mantel-Haenszel chi-square tests. 
Results:  Primary varicella hospitalization rates declined 82.9% from the pre-vaccine (1994-
1995) to the 1-dose (2001-2005) era (p<0.001).  Rates further decreased significantly in the 2-
dose era (2010-2012) only among 5 to 9 year olds. HZ hospitalization rates decreased in 
individuals 0-29 years and 30-39 years by 4.8%/year and 6.1%/year, respectively, from 2001-
2012.  Individuals <15 years experienced the largest decline, at 19.4%/year from 2001-
2012.  Among individuals >60 years, hospitalization rates increased by 5.1%/year from 2001-
2006 but then decreased by 4.2%/year from 2007-2012. 
Conclusions:  Introduction of the varicella vaccine appears to have had an impact on both 
varicella and HZ hospitalizations.  Varicella hospitalization rates decreased across all age groups 
following vaccine introduction, though the main impact occurred during the 1-dose era. HZ 
hospitalization rates decreased among individuals <15 years from 2001-2012, providing early 
evidence of varicella vaccine impact.  The increase in HZ hospitalization rates among individuals 
>60 years 2001-2006 may be due to decreased varicella virus circulation and lack of immune 
boosting.  However, the reduction in HZ morbidity from 2007-2012 suggests HZ vaccine, 
despite low usage rates, is offsetting the increase. Increased use of the HZ vaccine in individuals 
>60 years is needed to reduce hospitalization rates first to the levels seen prior to varicella 
vaccine introduction and then lower.  Ongoing surveillance for HZ is needed to monitor 
anticipated long-term changes in disease epidemiology; hospital discharge data is a feasible 




Over the past two decades, the Advisory Committee on Immunization Practices (ACIP) issued 
several important recommendations for vaccination against primary varicella and herpes zoster 
(HZ).  In the year after the licensure of the varicella vaccine in 1995, it was recommended that 
children aged 12-18 months receive 1 dose of the vaccine, and that susceptible children aged 19 
months-12 years receive a catch-up dose [1].  Following reports of leveling of varicella incidence 
after an initial decline, continued outbreaks in schools and waning immunity, the ACIP revised 
its recommendation in 2006 to include (1) two-dose vaccination in children, with the first dose 
administered at 12—15 months and the second at 4—6 years, (2) catch-up vaccination with a 
second dose for individuals who previously received one dose, and (3) two-dose vaccination of 
susceptible persons aged !13 years [2].  After the licensure of the herpes zoster vaccine 
(Zostavax®) in 2006, the ACIP recommended that individuals !60 years be vaccinated with a 
single dose of the vaccine [3]. 
Prior to 1995, it was estimated that 98.1% of the US population was infected by age 49 years 
[4]and that 10-30% of varicella-infected individuals would eventually develop herpes zoster [5].  
However, the introduction and widespread use of the varicella and HZ vaccines have the 
potential to modify the epidemiology of both diseases.   
For varicella, it has been shown that the incidence of varicella decreased sharply after the 1-
dose recommendation and decreased again after the 2-dose recommendation [6-8].  At the same 
time, it is expected that the average age at infection will increase due to lack of early exposure, 
and this may result in higher severe morbidity since complications are more common with older 
age [9]. 
For HZ, a long-term reduction in the incidence of disease is predicted to occur due to fewer 
people becoming infected with varicella.  It is also expected that there will be a reduction in 
incidence among adults aged 60 or older who receive the HZ vaccine.  At the same time, it has 
been hypothesized that there may be a short-term increase in the incidence of HZ due to a 
decrease in immune “boosting” that circulating varicella virus used to provide to adults 
previously infected with varicella [10]. 
Although public health surveillance is being conducted to monitor the impact of varicella 
vaccine on varicella incidence, few if any state health departments conduct ongoing surveillance 
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for HZ [6, 8]. Hospital discharge datasets provide an opportunity to monitor trends and possible 
vaccine impact at the population level and severe end of the disease spectrum.  
The epidemiology of primary varicella and herpes zoster requiring hospitalization in the 10 
years prior to the vaccine has been characterized in Connecticut [11].  However, to our 
knowledge, there are no reports of the epidemiology of HZ hospitalizations in the varicella and 
HZ vaccine eras and no reports of the additional impact of the 2-dose schedule on varicella 
hospitalizations.  
Data on hospitalizations in Connecticut were reviewed for the time period 1994-2012 to (1) 
establish the epidemiology of severe varicella and HZ disease in the post-vaccine eras and (2) 





Data sources:  The Connecticut Department of Public Health Office of Health Care Access 
Acute Care Hospital Inpatient Discharge Database was used to identify hospitalizations due to 
primary varicella or herpes zoster.  The database contains discharge information on all persons 
hospitalized at any one of the 30 acute care hospitals in CT. 
 
Study definitions:  The discharge database was examined for the period January 1, 1994 through 
December 31, 2012.  Cases were defined as any individual admitted during this period who had a 
discharge code of 052.xx for primary varicella (in any one of the ten diagnostic positions) or a 
discharge code of 053.xx for herpes zoster (in either the first or second diagnostic position).  All 
diagnostic positions were chosen for primary varicella so as to be inclusive of the small number 
of hospitalizations.  HZ was limited to diagnoses in the first two positions to capture incident 
cases and not persons with HZ incidental to the primary reason for hospitalization.  Patient 
records containing codes for both primary varicella and HZ were excluded from the analysis.  
For patients admitted multiple times, only the first hospitalization was included. 
 
Trends in the epidemiology of primary varicella were examined from the pre-vaccine period to 
the 1-dose era to the 2-dose era.  The pre-vaccine era was defined as 1994-1995, prior to the 
licensure of varicella vaccine.  The 1-dose era was defined as 2001-2005, the period in 
Connecticut prior to the 2-dose recommendation when the incidence of varicella was low and 
stable[12].  The 2-dose era was defined as 2010-2012, which gave sufficient time for the 2-dose 
recommendation to be largely implemented and some impact to have occurred.   For HZ, two 
time periods were examined for changes in incidence rates:  2001-2006, the period with low and 
stable varicella circulation prior to the licensure of the HZ vaccine, and 2007-2012, the period 
following its licensure. 
 
Demographic data:  Patient data available through the database included a unique patient ID, 
admission year, age, the principle diagnostic code and up to nine secondary discharge diagnostic 
codes, length of stay (LOS), and ZIP code of residence. 
Data on the percent of individuals living below the poverty level in a ZIP code tabulation 
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area (ZCTA) was extracted from the 2000 US Census and 2008-2012 American Community 
Survey 5-year estimate, and joined to the hospital dataset based on ZIP code.  The 2000 data 
were joined to cases admitted 1994-2004 and the 2010 data were joined to cases admitted 2005-
2012.  ZCTA-level poverty was categorized as 0-4.9%, 5-9.9%, 10-19.9%, or 20+% of residents 
of the ZCTA living below the federal poverty level based on recommendations by the Public 
Health Disparities Geocoding Project [13]. 
 
The same methodology using discharge diagnosis codes was used to classify patients with 
underlying conditions as in an earlier Connecticut study [11], with the exception that one new 
code for HIV was added to the search (V08) due to a national coding change implemented in 
1994 [14]. 
 
Statistical analysis:  Age-specific hospitalization rates were calculated for each year using 
intercensal denominator data for Connecticut obtained from the US Census Bureau (years 1994-
2011) and the annual Connecticut Department of Public Health population estimates (2012).  
Hospitalization rates by ZCTA-level poverty group were calculated using denominator data for 
Connecticut obtained from the 2000 US Census (for years 1994-2004) or the 2010 US Census 
(for years 2005-2012).  Age groups for varicella were <1 year, 1-4, 5-9, 10-14, 15-19, 20-29, 30-
39 and >40 years. For HZ they were 0-29, 30-39, 40-49, 50-59 and >60 years 
 
For primary varicella, changes in hospitalization rates from 1994-1995 to 2001-2005 to 2010-
2012 were examined by the Mantel-Haenszel chi-square test for trend.  Mantel-Haenszel chi-
square was also used to evaluate changes in the proportion of cases by age group and underlying 
conditions, and to test the significance of increasing hospitalization rates by increasing ZCTA-
level poverty group.  For herpes zoster, Poisson regression models were used to evaluate annual 
trends in age-specific hospitalization rates over the years from 2001-2012 (overall and for age 
groups <60 years), and from 2001-2006 and 2007-2012 (age groups >60 years). The Mantel-
Haenszel chi-square test for trend was used to evaluate changes in the proportion of HZ cases 




All statistical analyses were done with SAS 9.3 or Epi Info 7. 
 
This study was approved by the Yale University School of Medicine and Connecticut 





Overall hospitalization rate:  Over the 19-year study period, there were 1,181 hospital discharges 
for primary varicella.  After excluding those with concurrent varicella and HZ diagnoses (n=72) 
and multiple admissions of the same person (n=35), there were 1,074 unique persons with 
primary varicella-related discharges.  There was an annual average of 4.9 
hospitalizations/100,000 population in the pre-vaccine era, 0.8 hospitalizations/100,000 
population in the 1-dose era, and 0.7 hospitalizations/100,000 population per year in the 2-dose 
era (Table 1).  Hospitalization rates declined 82.9% from the pre-vaccine to the 1-dose era 
(p<0.001).  The additional 11.9% decrease from the 1-dose to the 2-dose era was not statistically 
significant. 
 
Age-specific hospitalization rate:  Age-specific hospitalization rates declined significantly within 
each age group from the pre-vaccine to the 1-dose era, with the largest declines (~90% each) 
seen among the three youngest age groups (Table 1).  Only the 5 to 9 year old age group 
experienced a significant (100%, p=0.01) decline from the 1-dose to the 2-dose era. 
 
Proportion of cases by age:  In the pre-varicella vaccine era, individuals aged 9 or younger made 
up 50% of the hospitalizations.  By 2001-2005, they made up ~20% and by 2010-2012 they 
made up ~10% (Fig. 1).  The majority of hospitalizations in the 2010-2012 period included 
individuals aged >40; there were no hospitalizations among children aged 5-9 (Fig. 1). 
 
ZCTA poverty level:  Prior to the introduction of the varicella vaccine, the hospitalization rate 
increased as ZCTA-level poverty increased. Persons living in high poverty ZCTAs had a 3.8-fold 
higher rate than those in the lowest poverty ZCTAs (Table 2).  The hospitalization rate and 
relative risk decreased from the 1-dose to the 2-dose era within all ZCTA poverty groups, 
although a significant disparity in the hospitalization rate still persisted as of 2010-2012 (Table 
2).   
 
Underlying Conditions: The overall prevalence of having at least one underlying condition was 
!
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25.1% and did not change during the three time periods (Table S1).  
HZ 
Overall hospitalization rates:  Over the 19-year study period, there were 14,089 hospital 
discharges for HZ.  After excluding those with concurrent varicella and HZ diagnoses (n=72), 
multiple admissions of the same person (n=2,348), and those with tertiary or higher DX codes 
(n=6,976), there were 4,693 unique persons with HZ-related discharges.  From 1994-2000, 
hospitalization rates did not change significantly over time (Figure 2, Table S2).  For the time 
period 2001-2012, there was a significant relationship between year and the hospitalization rate, 
with an average 2.2% increase per year in the hospitalization rate (Fig. 2).  However, while 
2001-2006 rates increased significantly at 3.8% per year, 2007-2012 rates decreased significantly 
by 1.8% per year.  
 
Age-specific hospitalization rates:  During 1994-2000, rates did not change significantly within 
any age group, except for a marginally significant decrease in the 40-49 age group (p=0.046) 
(Table S2). 
 
During 2001-2012, only the two youngest age groups experienced a significant decrease in the 
hospitalization rate, with rates decreasing by 4.8% each year among 0-29 year olds and by 6.1% 
among 30-39 year olds (Figure 3, Table S3).  When the 0-29 age group was divided into two 
groups aged 0-14 and 15-29, only the 0-14 age group experienced a significant decrease in the 
hospitalization rate from 2001-2012 (19.4% per year, p<0.001) (Fig. 3, Table S3a). This decrease 
was of the same magnitude for both those with an underlying condition and those with no 
underlying conditions (Table S3b). 
 
When cases with an HIV diagnosis were excluded, the measured drop in HZ incidence in 30-39 
year olds disappeared, and there was no change in the proportion of those remaining with 
underlying conditions (25.0% overall) (Tables S4, S5). In the 0-29 age group, however, a 
decrease in the hospitalization rate was still observed, and there remained a decrease in the 




For individuals >60, there was a 5.1% increase in the hospitalization rate each year from 2001-
2006 (p=0.031) switching to a 4.2% annual decrease from 2007-2012 (p<0.001) (Figure 3, 
Tables S6, S7).  When an age-stratified analysis was performed using 5-year age groups to 
examine whether a specific age group was driving each trend, there was no difference between 
the rates at which each age group increased (Table S6). However, for the 2007-2012 decrease, 
those 60-79 years had a more pronounced decrease (5.8% per year, p=0.013) than those >80 
(1.8% per year, p=0.415) (Table S7).  
 
None of these trends were changed when the excluded 6,000+ persons with discharge HZ 
diagnoses in the 3rd or later positions were included.  
 
We looked at median LOS as a possible indicator of changed diagnostic criterion to explain the 
progressive changes in incidence over time. There were no changes in median LOS (4 days) 
during 2001-2012 in those 0-14 years, or during 2001-2006 or 2007-2012 in those >60 years. 
 
Underlying conditions:  Overall, the proportion of cases with an underlying condition decreased 
from 28.4% in the pre-vaccine era to 20.3% in 2001-2006 to 16.0% in 2007-2012 (p<0.001) 
(Table 3).  When an age-stratified analysis was performed, only the three youngest age groups 
had a significant decrease in the proportion of cases with an underlying condition (Table 3).  
 
When the time periods 2001-2006 and 2007-2012 were examined for changes in the annual 
proportion of cases with an underlying condition among cases >60 years, no significant trends 
were observed (Tables S8, S9). 
 
ZCTA poverty level:  No significant association was found between ZCTA poverty level and 
incidence of HZ hospitalization for the time periods 1994-1995 and 2007-2012.  However, 
during 2001-2006, persons living in the highest poverty ZCTAs had a 1.25-fold higher rate of 




We found evidence that the introduction and widespread use of varicella vaccine may have had 
an impact not just on varicella hospitalizations, but on herpes zoster hospitalizations as well. In 
addition, we found that the switch from the 1-dose to the 2-dose varicella vaccine 
recommendation in 2006 has had only a very modest impact on varicella hospitalizations thus far, 
and that the introduction of HZ vaccine may be having an impact on HZ trends. These findings 
have implications for surveillance for HZ and for more aggressive use of the HZ vaccine. 
We detected a significant decrease in the HZ hospitalization rate in the two youngest age 
groups (0-29 and 30-39) from 2001-2012. There are at least two possible explanations for our 
findings: 1) reduction in the prevalence of underlying conditions that are associated with a higher 
risk of HZ, and 2) a vaccine induced reduction in the number of persons with latent wild 
varicella infection.  Both the 0-29 and 30-39 age groups had significant decreases in the 
proportion of cases with an underlying condition that was partially explained by a decrease in the 
proportion of cases with HIV.  It is possible that the decline in HIV perinatal transmission since 
the 1990s and increasing use of highly active anti-retroviral therapy (HAART) may explain some 
of the decrease in the HZ hospitalization rate among these age groups [15].  Additionally, the 
reduction in varicella incidence since the introduction of the vaccine could contribute to the 
lowered HZ hospitalization rates.  This is supported by our finding that the 0-14 age group, 
including both those with and without underlying conditions, experienced a significant decline in 
the hospitalization rate from 2001-2012 and suggests that varicella vaccination has had an impact 
on herpes zoster rates among the age groups targeted for varicella vaccination.  
In contrast to the trends observed in the two youngest age groups, we detected a 
significant increase in the hospitalization rate in the >60 age group from 2001-2006 and a 
decrease from 2007-2012. This increase could not be explained by an increase in the proportion 
of cases with underlying conditions or reduction in the threshold for admitting persons with HZ 
to the hospital as measured by LOS.  The main remaining hypothesis is that hospitalization rates 
increased because of decreased boosting from natural varicella.  Studies in the literature have 
been mixed regarding the effect of boosting on herpes zoster epidemiology.  Data from the 
Antelope Valley Varicella Surveillance Project on HZ incidence suggest that HZ incidence 
increased during the 1-dose varicella vaccine era, though baseline data were not available prior 
!
! *$!
to the introduction of the varicella vaccine [16].  Other studies have used medical claims data to 
examine changes in HZ over time.  One study conducted during a comparable time period (1993-
2004) detected a significant increase in population-adjusted HZ hospitalization rates in 2003-
2004 compared to 1993-2001 [17].  Another study that examined health insurance claims data 
from 1993-2006 found that HZ rates trended upwards across all age groups since 1993, prior to 
the introduction of the varicella vaccine [18].  By contrast, we did not detect changes in the HZ 
hospitalization rate from 1994-2000. 
The decrease in HZ hospitalization rates from 2007-2012 could not be explained by a 
reduction in the proportion of cases with an underlying condition, and is suggestive of vaccine 
impact.  National herpes zoster vaccine coverage data indicate that vaccine uptake among the 
60+ age group has increased from 6.7% in 2008 to 20.1% in 2012 [19, 20].  
We found a significant decrease in primary varicella hospitalization rates in the 1-dose 
vaccine era compared to the pre-vaccine era across all age groups, and a significant change only 
among those 5-9 from the 1-dose era to the 2-dose era.  Only one other study has examined the 
impact of 2-dose vaccination on hospitalization rates, and this study reported a >40% overall 
decrease in varicella-related hospitalizations from the 1-dose era (2002-2005) to the 2-dose era 
(2006-2010) [6].  However, this study did not note whether this decline was significant or age-
group specific.  Our study did not include data on vaccination status of hospitalized patients, so it 
is not possible to ascribe the changes in the hospitalization rate to the 2-dose vaccine 
recommendation itself.  However, our finding of a reduction in varicella morbidity among 5 to 9 
year olds in the 2-dose vaccine era is consistent with this age group being targeted for the 2nd 
varicella vaccine dose. 
The association between higher ZCTA-level poverty and higher primary varicella 
hospitalization rates has persisted from the pre-vaccine era through to the 2-dose era, though the 
gap in incidence between the lowest poverty group and the highest poverty group has decreased 
over the years.  To our knowledge, no other study has reported on the association between 
varicella hospitalizations and poverty.  However, we would expect that vaccination would 
eliminate disparities due to the Vaccines for Children Program and the fact that CT has 
mandatory school-age vaccine requirements.  It has been suggested that adolescents eligible for 
the Vaccines for Children Program may not be receiving both doses of the vaccine [21].  
!
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Combined with the fact that CT’s school-age entry requirement was not put in effect until 2011 
for 7th graders, it is possible that children and adolescents from higher poverty ZCTAs may have 
been relatively under-vaccinated during the 2010-2012 time period that was examined.  Studies 
are needed to examine this link elsewhere. 
The analysis of this study has several limitations.  First, the ICD-9 coding that was used 
for case ascertainment is prone to coding errors and discharge diagnosis assignment.  Since no 
attempt was made to validate the discharge diagnosis codes, it was not possible to distinguish 
between hospitalizations due to primary varicella or HZ infection incidental to the primary 
reason for hospitalization versus hospitalizations where primary varicella or HZ infection was 
the primary reason for hospitalization.  This could lead to an over-estimate of the hospitalization 
rates for each disease.  For HZ, we attempted to minimize this bias by using only the first or 
second diagnostic position to identify cases.  For primary varicella, however, it is possible we 
overestimated hospitalization rates, since a primary varicella code in any DX position was 
classified as primary varicella.  Another limitation is that no information on patient vaccination 
history was obtained, so it is not possible to directly attribute changes in hospitalization rates to 
each of the vaccines.  Third, for primary varicella, the 2010-2012 time period that was examined 
for changes in the hospitalization rate may have been too close to initiation of the 2-dose 
recommendation to fully evaluate its impact.  Similarly, the evaluation of possible decreases in 
HZ hospitalizations in younger age groups as a result of decreased circulation of varicella and in 
older age groups as a result of HZ vaccine may have been too soon to see their effects. National 
HZ vaccination coverage ranged from 6.7% in 2008 to 20.1% in 2012 [19, 20] and the first 
varicella cohorts to have fully benefited from varicella vaccine are children born in the 1990s, 
i.e., <20 years ago. 
In summary, this study reports on changes in the epidemiology of severe primary 
varicella and herpes zoster disease requiring hospitalization, and highlights characteristics of 
individuals who continue to bear the burden of disease.  Findings from this study add to the body 
of evidence that is consistent with vaccine impact on primary varicella and with a short-term 
increase in herpes zoster morbidity among the oldest age groups.  This study also provides early 
evidence of varicella vaccine impact on herpes zoster among individuals under the age of 15 
years, as well as early evidence of herpes zoster vaccine impact on individuals aged >60.  These 
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findings suggest that more aggressive use of the herpes zoster vaccine is needed among adults 
>60 years to offset the possible effect of lack of boosting from circulating varicella.  Additionally, 
long-term monitoring is needed to assess whether these early reductions in HZ hospitalizations 
continue over time.  Since there is no formal surveillance system for HZ in the US, hospital 
discharge data are a practical method for monitoring long-term changes in the epidemiology of 
HZ.  Caution should be taken with the interpretation of this study due to its ecological design, 
and more research is needed to understand the associations between age, poverty, and underlying 
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Table 1. Reported nos. of primary varicella hospitalizations and rates, 1994-1995, 2001-2005, and 2010-2012 
            





















Overall 324 4.9   145 0.8   79 0.7   -4.0*** -0.1 
Age group            
<1 
30 
(9.3) 33.7   
9 
(6.2) 4.3   
4 
(5.1) 3.6   -29.4*** -0.7 
1--4 
78 
(24.1) 20.5  
12 
(8.3) 1.4  
4 
(5.1) 0.8  -19.1*** -0.5 
5--9 
55 
(17.0) 11.6   
11 
(7.6) 0.9   
0 
(0.0) 0.0   -10.7*** -0.9* 
10--14 
7 
(2.2) 1.6  
4 
(2.8) 0.3  
2 
(2.5) 0.3  -1.3** 0.0 
15--19 
12 
(3.7) 3.0   
12 
(8.3) 1.0   
5 
(6.3) 0.7   -2.0** -0.4 
20--29 
60 
(18.5) 6.7  
13 
(9.0) 0.7  
8 
(10.1) 0.6  -6.1*** -0.1 
30--39 
49 
(15.1) 4.2   
24 
(16.6) 1.0   
13 
(16.5) 1.0   -3.3*** 0.1 
>=40 
33 
(10.2) 1.2   
60 
(41.4) 0.7   
43 
(54.4) 0.8   -0.4* 0.1 
*<0.05            
**<0.01            
***<0.001            
 
 
Table 2. Primary varicella and herpes zoster hospitalization rates by ZCTA-level poverty and time period 
















1994-1995     1994-1995    
0-4.9% 3.2 1.00 <0.001      0-4.9% 4.9 1.00 0.044 
5.0-9.9% 3.7 1.16       5.0-9.9% 7.5 1.55  
10.0-19.9% 7.1 2.23       10.0-19.9% 7.2 1.48  
>=20% 12.1 3.83   >=20% 6.6 1.36  
2001-2005     2001-2006    
0-4.9% 0.6 1.00 <0.001      0-4.9% 6.3 1.00 0.006 
5.0-9.9% 0.7 1.22       5.0-9.9% 7.4 1.17  
10.0-19.9% 1.0 1.62       10.0-19.9% 7.5 1.20  
>=20% 1.8 3.03   >=20% 7.9 1.25  
2010-2012     2007-2012    
0-4.9% 0.6 1.00 0.012      0-4.9% 7.5 1.00 0.679 
5.0-9.9% 0.7 1.28       5.0-9.9% 8.3 1.10  
10.0-19.9% 0.7 1.24       10.0-19.9% 8.9 1.19  
>=20% 1.3 2.23   >=20% 7.7 1.03  
*chi-square test for linear trend within individual time periods 
 
 
Table 3. Proportion of hospitalized herpes zoster cases with an 
underlying condition 
Age 1994-1995 2001-2006 2007-2012 p-value* 
Overall 28.4 20.3 16.0 <0.001 
Age group    
0-29 59.3 31.5 29.9 0.024 
30-39 69.2 51.6 37.5 0.002 
40-49 54.2 47.2 29.5 0.001 
50-59 18.8 26.0 22.9 0.932 
60+ 15.6 11.8 11.8 0.193 














Table S1 Proportion of hospitalized primary varicella cases 
with an underlying condition 
Age 1994-1995 2001-2005 2010-2012 p-value* 
Overall 24.4 29.7 27.9 0.460 
Age group     
<1 0.0 11.1 0.0 0.145 
0-4 10.3 8.3 25.0 0.623 
5--9 14.6 18.2 N/A** 0.759 
10--14 0.0 25.0 0.0 0.602 
15-19 41.7 25.0 40.0 0.664 
20-29 36.7 15.4 62.5 0.088 
30-39 51.0 41.7 30.8 0.390 
40+ 33.3 38.3 23.3 0.270 
*Mantel-Haenszel chi-square test for trend 
**No hospitalizations during time period 
 
Table S2. Herpes zoster hospitalization rate regression 
model (year as predictor), 1994-2000 
Age ! Year exp !  % change p-value 
Overall 0.0034 1.00 0.34 0.793 
Age Group     
0-29 0.0238 1.02 2.41 0.610 
30-39 0.0178 1.02 1.80 0.677 
40-49 -0.0821 0.92 -7.88 0.046 
50-59 -0.0085 0.99 -0.57 0.836 
60+ 0.0133 1.01 1.34 0.417 
 
Table S3a. Herpes zoster hospitalization rate regression 
model (year as predictor), 2001-2012 
Age ! Year exp !  % change p-value 
Overall 0.0214 1.02 2.16 <0.001 
Age Group     
0-29 -0.049 0.95 -4.78 0.036 
0-14 -0.2156 0.81 -19.39 <0.001 
15-29 0.0047 1.00 0.47 0.867 
30-39 -0.0631 0.94 -6.12 0.009 
40-49 0.0066 1.01 0.66 0.722 





Table S3b. Herpes zoster hospitalization rate regression 
model (year as predictor) among 0-14 year olds, 2001-
2012  
Age ! Year exp !  % change p-value 
All 0-14 -0.2156 0.81 -19.39 <0.001 
No UCs -0.2142 0.81 -19.28 <0.001 
>=1 UC -0.2194 0.80 -19.70 0.021 
 
Table S4. Herpes zoster hospitalization rate regression 
model (year as predictor), excluding individuals with 
HIV, 2001-2012 
Age ! Year exp !  % change p-value 
Overall 0.0253 1.03 2.56 <0.001 
Age group     
0-29 -0.0571 0.94 -5.55 0.023 
30-39 -0.0278 0.97 -2.74 0.337 
40-49 0.0212 1.02 2.14 0.326 
50-59 0.0199 1.02 2.01 0.199 
60-64 0.0061 1.01 0.61 0.787 
65-69 -0.0049 1.00 -0.49 0.802 
70-74 0.0262 1.03 2.65 0.126 
75-79 0.0186 1.02 1.88 0.193 
80-84 0.0323 1.03 3.28 0.016 
85+ 0.0372 1.04 3.79 <0.001 
 
Table S5. Proportion of hospitalized herpes zoster cases with an 
underlying condition, excluding HIV 
Age 1994-1995 2001-2006 2007-2012 p-value* 
Overall 18.4 14.7 12.3 0.002 
Age group     
0-29 42.1 24.7 17.5 0.044 
30-39 33.3 23.0 18.6 0.242 
40-49 21.4 22.0 12.2 0.107 
50-59 16.1 18.8 13.8 0.331 
60-64 41.4 14.8 23.2 0.306 
65-69 23.1 18.4 20.3 0.822 
70-74 19.6 16.2 16.3 0.751 
75-79 3.6 10.4 11.1 0.140 
80-84 15.3 14.4 9.2 0.080 





Table S6. Herpes zoster hospitalization rate 
regression model (year as predictor), 2001-2006 
Age ! Year exp !  % change p-value 
60+ 0.0493 1.05 5.05 0.031 
60-64 0.0525 1.05 5.39 0.446 
65-69 0.023 1.02 2.33 0.701 
70-74 0.0766 1.08 7.96 0.145 
75-79 0.0529 1.05 5.43 0.199 
80-84 0.0686 1.07 7.10 0.090 
85+ 0.0394 1.04 4.02 0.271 
60-79 0.0422 1.04 4.31 0.109 
80+ 0.0539 1.06 5.54 0.044 
 
Table S7. Herpes zoster hospitalization rate regression 
model (year as predictor), 2007-2012 
Age ! Year exp !  % change p-value 
60+ -0.0432 0.96 -4.23 0.009 
60-64 -0.0474 0.95 -4.63 0.487 
65-69 -0.0914 0.91 -8.73 0.084 
70-74 -0.0658 0.94 -6.37 0.164 
75-79 -0.0132 0.99 -1.31 0.745 
80-84 -0.0119 0.99 -1.18 0.744 
85+ -0.0271 0.97 -2.67 0.339 
60-79 -0.06 0.94 -5.82 0.013 
80+ -0.0182 0.98 -1.80 0.415 
 
Table S8. Proportion of herpes zoster cases with an underlying condition, 
2001-2006 
Age group 2001 2002 2003 2004 2005 2006 p-value* 
60+ 12.1 13.8 10.7 11.3 12.4 10.7 0.56 
*Mantel-Haenszel chi-square test for trend 
 
Table S9. Proportion of herpes zoster cases with an underlying condition, 
2007-2012 
Age group 2007 2008 2009 2010 2011 2012 p-value* 
60+ 12.7 12.8 12.2 12.4 10.8 9.4 0.2307 
*Mantel-Haenszel chi-square test for trend 
 
